- Champions Oncology (CSBR, Financial) partners with Turbine to enhance biopharma drug discovery workflows.
- The collaboration integrates multi-omic datasets with virtual cell simulation technology.
- This strategic alliance aims to accelerate drug development and reduce reliance on traditional lab methods.
Champions Oncology (CSBR) has announced a strategic collaboration with Turbine, the developers of an advanced virtual cell simulation platform. This partnership aims to revolutionize drug discovery workflows in the biopharma sector by integrating Champions' extensive multi-omic dataset with Turbine's cutting-edge simulation technology.
By combining Champions' clinically annotated datasets with Turbine's platform, researchers can conduct in silico experiments that offer greater speed and precision. This innovative approach is designed to enhance various aspects of drug discovery, from target identification to generating mechanistic insights, while minimizing the dependency on traditional laboratory methods.
The partnership leverages Champions' unique offering of deeply characterized patient samples, accompanied by in vivo experimental results and clinical outcome data. This integration is critical for training and validating simulations that predict treatment responses, providing a competitive advantage in the drug development market.
Champions Oncology CEO Ronnie Morris commented on the collaboration, stating that it addresses key limitations in traditional R&D and accelerates the path to smarter, faster drug development. Turbine's Co-founder & CSO Daniel Veres highlighted the unique integration of real-world translational relevance provided by Champions, which is essential for accurate predictive simulations.
This strategic partnership reflects the broader industry shift towards computational approaches in drug development, positioning Champions Oncology to expand the utility and market reach of their proprietary datasets.
